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Abstract
Background—Polyomavirus nephropathy (PVAN) is a common cause of kidney allograft 
dysfunction and loss. To identify PVAN-specific gene expression and underlying molecular 
mechanisms we analyzed kidney biopsies with and without PVAN.
Methods—The study included 168 posttransplant renal allograft biopsies (T cell mediated 
rejection=26, PVAN=10, normal functioning graft (STA) =73, and interstitial fibrosis/tubular 
atrophy (IF/TA) =59) from 168 unique kidney allograft recipients. We performed gene expression 
assays and bioinformatics analysis to identify a set of PVAN-specific genes. Validity and relevance 
of a subset of these genes are validated by QPCR and IHC.
Results—Unsupervised hierarchical clustering analysis of all the biopsies revealed high 
similarity between PVAN and TCMR gene expression. Increased statistical stringency identified 
158 and 252 unique PVAN and TCMR injury-specific gene transcripts respectively. While TCMR-
specific genes were overwhelmingly involved in immune response costimulation and TCR 
signaling, PVAN-specific genes were mainly related to DNA replication process, RNA polymerase 
assembly and pathogen recognition receptors. A principal component analysis using these genes 
further confirmed the most optimal separation between the 3 different clinical phenotypes. 
Validation of 4 PVAN-specific genes (RPS15, CFD, LTF, and NOSIP) by QPCR and confirmation 
by immunohistochemistry of 2 PVAN-specific proteins with anti-viral function (LTF and IFITM1) 
was done.
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Conclusions—In conclusion, even though PVAN and TCMR kidney allografts share great 
similarities on gene perturbation, PVAN-specific genes were identified with well-known anti-viral 
properties that provide tools for discerning PVAN and AR as well as attractive targets for rational 
drug design.
Introduction
Polyomavirus-associated nephropathy (PVAN) remains an important opportunistic infection 
after renal transplantation. Asymptomatic viremia may be observed in 10-30% of transplant 
recipients, and 4-10% may develop PVAN with allograft loss occurring in approximately 
50% of cases 1-4. Even though immunosuppressive condition is the main cause for viral 
reactivation, not all latent infections in Kidney transplant patients lead to the development 
PVAN. This suggests that while the increased burden of immunosuppression appears to be 
crucial for viral reactivation, individual immune-susceptibility to viral infection and type of 
intragraft inflammation are likely to be involved in the pathogenesis of PVAN 5.
BKV replication can rapidly be monitored by nucleic acid testing (q-PCR) analysis of urine 
or plasma samples. The diagnosis of PVAN requires histological assessment showing typical 
viral cytopathic changes in tubular epithelial cells and a positive immunostaining against the 
LT antigen of simian polyomavirus (SV40). Importantly, accompanying these lesions, there 
is an important tubulo-interstitial inflammatory cell infiltrate, which is indistinguishable 
from typical histological patterns of that observed in acute T cell mediated rejection 
(TCMR) 6,7. This is of clinical relevance since the therapeutic approaches are opposed; 
PVAN treatment fundamentally focuses on a progressive reduction of immunosuppression 
with eventual adjuvant medication, whereas TCMR requires of additional rescue 
immunosuppressive therapy (8). Therefore, an accurate recognition of the PVAN-associated 
molecular fingerprint could help to better discriminate these 2 processes and provide new 
insight of the pathogenic mechanisms of the disease.
Gene expression studies in biopsy samples of PVAN and TCMR focusing at specific genes 
by PCR analysis have reported a similar over-expressed transcripts associated with similar T 
cell activation and costimulation pathways such as IFN-ɣ, perforin, CXCR3 or CD40/
CD40L, respectively 8,9. Likewise, in the urine, increased inflammatory cytokines similar to 
TCMR have also been shown in PVAN patients 10,11. However, the evaluation using high-
throughput microarray analysis of PVAN/TCMR tissue allograft samples to significantly 
enrich the genomic picture of these pathological features is scarce. Recently, Lubetzky et 
al 12 investigated the genomics of PVAN, mainly in whole blood and in a reduced number of 
tissue allograft samples by microarray analysis. Authors reported a significantly increased 
pathogenesis-based transcript activity of cytotoxic T cells and natural killer cells in PVAN 
resembling TCMR, suggesting the involvement of adaptive and innate immunity in both 
settings.
With the aim of obtaining a deeper understanding of the main molecular mechanisms taking 
place during the inflammatory process both in PVAN and TCMR, we employed a high 
throughput microarray analysis of kidney allograft biopsies. Here, we report that while both 
pathological features overlap with a relevant number of inflammatory and cytotoxic 
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pathogenesis-related transcripts, PVAN does also show differentially up-regulated gene-
transcripts related to immune response to organisms and particularly to viral infection. 
Importantly, significantly over-expressed genes and gene products (proteins) in PVAN 
patients were further confirmed by qPCR and IHC.
Materials and Methods
Patients and biopsies
The study comprised of 168 posttransplant renal allograft biopsies (TCMR=26, PVAN=10, 
normal functioning graft without subclinical rejection or other injury (STA) =73, and 
interstitial fibrosis/tubular atrophy (IF/TA) =59) from 168 unique pediatric and adolescent 
kidney allograft recipients (1 to 21 years of age) (Table 1). All patients received an 
immunosuppressive regimen consisting of a combination of tacrolimus (Prograf, Astellas 
Pharma), mycophenolate mofetil (Cellcept, Hoffman-La Roche) and daclizumab (Zenapax, 
Hoffman-La Roche) or thymoglobulin (Sanofi) induction. Some patients received a steroid-
avoidance regimen, while others received a steroid-based immunosuppressive regimen, as 
previously described 13. Clinical and histological demographic characteristics were collected 
for all the biopsies. A subset of biopsies with PVAN, TCMR, and STA phenotypes, matched 
for major clinical variables such as recipient and donor age, % living donor kidneys, time 
posttransplant, immunosuppression usage, which was used as selected case-controls for 
more stringent analysis for PVAN biology (Table 1). Diagnosis of TCMR and IFTA was 
made by biopsy histology Banff classification 14. All IF/TA samples showed Banff scores 
grade II or higher, without showing any other specific accompanying lesions or AR. PVAN 
was defined as positivity of polyomavirus PCR in peripheral blood, together with a positive 
SV40 stain in the concomitant renal allograft biopsy according to Banff criteria15. A small 
number of patients had BK DNA replication but no evidence of PVAN on biopsy; these 
patients are categorized as BKVB (BK viremia in blood only) and have been included in the 
global gene expression first phase analysis in Table 1 and Figure 1. The Ethics Committee of 
Stanford University Medical School and UCSF Medical Center approved the study. All 
patients/guardians provided informed consent to participate in the research, in full adherence 
to the Declaration of Helsinki. The clinical and research activities being reported are 
consistent with the Principles of the Declaration of Istanbul as outlined in the ‘Declaration of 
Istanbul on Organ Trafficking and Transplant Tourism.
RNA Extraction, Quality Control, Amplification and Microarray Hybridization
Needle biopsies were collected at the time of biopsy procedure and immediately submerged 
in RNAlater (Qiagen, Valencia, CA) and stored at −80 °C until use. For the gene expression 
analysis purpose, total RNA was extracted and hybridized to Affymetrix GeneChip Human 
Genome U133 Plus 2.0 Arrays as previously described in Naesens et al 16. For processing 
and normalization of the scanned images, dChip 2006 software was used, with perfect match 
[PM]/mismatch [MM] difference modeling and invariant set normalization 17.
QPCR verification
A total of 250 ng total RNA was first reversed transcribed into complementary DNA 
(cDNA) using Superscript II (Invitrogen, Life Technologies, Foster City, CA, USA) 
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according to the manufacture's protocol in the Eppendorf vapo.protect thermal cycler 
(Eppendorf, Hauppauge, NY, USA). From each sample 1.56 ng cDNA were amplified in a 
target specific amplification step for 4 genes (RPS15, CFD, LTF, NOSIP) TaqMan PreAmp 
Master Mix (Cat. No. 4488593, Life Technologies, Foster City, CA, USA and TaqMan 
Primers and Probes (RPS15- Cat. No. Hs01358643_g1; CFD- Cat. No. Hs00157263_m1; 
LTF- Cat. No. Hs00914334_m1; NOSIP- Cat. No. Hs00211028_m1; Life Technologies, 
Foster City, CA, USA) for a total of 18 amplification cycles. QPCR reactions were 
performed in the BioMark RT PCR system using 18S gene (Primer and probe Cat. No. 
Hs03003631_g1, Life Technologies, Foster City, CA, USA) as a house keeping gene and 
Human XpressRef Universal Total RNA (Qiagen Inc, Valencia, CA, Cat. No. 338112) as a 
reference RNA for a total of 40 cycles (Fluidigm, San Francisco, CA, USA). Resulting chip 
data was initially analyzed for QC using the BioMark Analysis Software Version 2.0 
(Fluidigm, San Francisco, CA, USA) and Ct values were exported into Excel.
Immunohistochemistry of kidney allograft biopsies
Nine representative cases of kidney allograft biopsies of PVAN (n=3), TCMR (n=3) and 
STA (n=3) were stained for 2 over-expressed transcripts in PVAN kidney biopsies. To 
determine the extent of renal damage and classify them into the 3 different phenotypes 
(PVAN, TCMR and STA), all renal biopsies were analyzed by 2 blinded pathologists. The 
biopsies were probed with rabbit polyclonal to Lactoferrin (Abcam, Cambridge, MA), rabbit 
polyclonal to IFN-inducible transmembrane 1 (IFITM-1) (Abcam, Cambridge, MA) and 
SV40 (Becton Dickinson, Madrid, Spain). Immune staining in formalin-fixed, paraffin-
embedded tissues was performed as described previously 18-20. As positive controls for LTF, 
IFITM1 and SV40 human tonsil, liver carcinoma and kidney allograft paraffin-embedded 
tissues were used as positive controls, respectively. To quantify LTF and IFITM1 expression 
a semi quantitative score from 0 to 3 in the different compartments of the kidney (glomeruli, 
vessels, tubuli and interstitium) was used.
Data Processing and Analysis
Differentially expressed genes between biopsy groups were identified using an empirical 
Bayes moderated t-test using a Benjamini-Hochberg adjusted adjustment in the program 
AltAnalyze version 2.0.8 21. In all comparisons an FDR adjusted p<0.05 was used for 
filtering. After identifying the differentially expressed genes, these probe sets were analyzed 
using GO-Elite version 1.2.6 with all available default annotation resources 21-24 to identify 
enriched biological pathways, Ontologies and gene-sets. To evaluate immune cell 
infiltration, immune cell-type specific markers were computationally inferred using a new 
marker identification algorithm (LineageProfiler) applied to 2 large published microarray 
studies (GSE22886, GSE15907) to be used by GO-Elite. Principal component analysis 
(PCA), expression clustering (hierarchical or HOPACH), pathway filtering and visualization 
were also performed in AltAnalyze using the default parameters. The raw data sets for the 
168 biopsies included are deposited at the Gene Expression Omnibus under GSE72925.
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During the time-frame period of the study, 168 unique pediatric kidney allograft biopsies 
indicated either for cause or protocol, were initially included. Subsequently, 55 out of the 
168 sample-set with matched demographics were included for the gene expression analysis. 
10 (~18%) patients were found to have Polyomavirus-associated nephropathy (PVAN) (70% 
Stage C and 30% Stage B)15, 15 of 55 (~27%) pure T cell mediated rejection (TCMR) and 
30 of 55 (~55%) were considered as patients with stable functioning graft (STA) as no 
abnormalities were observed in their biopsies. As shown in Table 1, there were no 
differences regarding main clinical demographic characteristics such as donor and recipient 
age and gender, type of maintenance and induction immunosuppression, number of previous 
transplants and type of transplant. All biopsies were performed during the first 24 months 
after transplantation, either for protocol (at 6 or 24 months) or for cause because of allograft 
dysfunction or presence of BK DNA replication in peripheral blood. At the time of 
assessment, allograft function was not different between the 3 groups. Only the acute 
inflammatory Banff scores in the tubuli and interstitium of renal allograft compartments 
were significantly higher among PVAN and TCMR as compared to STA patients. The mean 
serum creatinine value of selected 15 TCMR patients was significantly higher (1.6 mg/dL) 
than the mean serum creatinine value of selected 30 STA patients (0.85 mg/dL) (p<0.001). 
The relatively lower serum creatinine seen in AR in this cohort is a function of this being a 
pediatric cohort. As per definition, only PVAN patients showed positivity for SV40 
immunostaining and BK DNA replication in peripheral blood. Five patients with Bk virus 
presence only in the blood (BKVB) were included in the cohort of normal biopsies.
Unsupervised hierarchical clustering of all kidney allograft biopsies
First, unsupervised hierarchical clustering analysis was performed among all 168 
posttransplant renal allograft biopsies with the aim of having a broad gene expression 
picture using the 500 top ranked probesets based on an FDR adjusted f-test p-value (p<0.05 
and 2-fold increase expression). This analysis indicated that the global gene expression 
pattern of samples classified as PVAN were largely similar to TCMR samples as both 
compared to normal kidney biopsies (Figure 1). The 5 biopsies with BKVB aligned with 
normal biopsies and were not studies as a separate phenotype. The top 500 genes were 
enriched in immune system process (p=3.38E-21) and immune response (p=3.38E-21).
Distinctive gene set expression for PVAN and TCMR as compared to STA in well-matched 
kidney transplant patients
Next, in order to have the most comparable study population, we selected for each PVAN 
(n=10) and TCMR (n=15) patients, the best demographically matched STA patient for this 
analysis (n=30). With a FDR adjusted p-value criteria of P<0.05, a total of 4047 probesets 
showed TCMR specific regulation of that 2483 probesets were significantly upregulated and 
1564 were significantly downregulated). With the same FDR adjusted p-value criteria of 
P<0.05, a total of 11594 probsets showed PVAN specific regulation of that 5450 probesets 
were significantly upregulated and 6144 were significantly downregulated). Among 
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upregulated genes 241 probesets were common in both TCMR and PVAN and among 
downregulated genes 332 probesets were common in both TCMR and PVAN tissues.
Using Principle Component Analysis (PCA) and taking into account the 150 top ranked 
probesets based on a FDR adjusted p-value (p<0.05 and 2-fold increase expression), a 
significant clustering of genes were observed among TCMR and STA as well as PVAN and 
STA. PVAN and TCMR samples clustered together when all 3 sample types were used in the 
PCA plot (Supplemental Figure 1).
With the aim of identifying critical PVAN injury-specific genes and in TCMR, we increased 
stringency of the specificity to the p value <0.01 with >2 fold increased expression that 
resulted in 209 unique genes increased in PVAN (Supplemental Table 1) and 252 unique 
genes increased in TCMR as compared to STA kidney biopsies. The TCMR-specific 
probesets that were not significant in PVAN and STA individuals were basically involved in 
CTLA4 (CD3G, CD28, CD3E, PIK3CG, PIK3R5, CD86, CD8A) and T cell receptor 
(NFATC2, CD8A, LCP2, ITK) signaling in cytotoxic T lymphocytes as well as related to 
cellular movement (CCL4, CCR5, CCR7, FAM65B) of T lymphocytes. Regarding the 115 
unique probesets most significantly enriched in PVAN and not in TCMR and STA patients, 
were mainly involved in DNA replication and RNA binding (BST2, EIF3G, F13A1, FGFR1, 
HSPD1, IFITM1, LTF, RPS15, NOSIP, and RARRES3), assembly of RNA polymerase 
(POLR2I, TAF10) and pathogen recognition receptors (C3, C1QA, C3AR1 and CFD). As 
indicated by both principal component analysis and HOPACH gene clustering of these 
PVAN specific genes, the most optimal separation between the 30 STA, 15 TCMR and 10 
PVAN samples was achieved, relative to any of the prior gene sets (Figures 1B and 1C).
To determine the functional relevance of genes enriched in PVAN but not TCMR, we 
performed a comprehensive pathway/gene-set analysis using the software GO-Elite. This 
analysis showed enrichment of 2 distinct set of pathways. Immune system related pathways 
such as complement cascade, TCR signaling, innate immune system, adaptive immune 
system were specific to TCMR associated genes whereas PVAN associated genes were 
enriched with DNA replication pathways such as mRNA processing, ribosomal scanning, 
viral mRNA translation etc. and metabolic pathways such as urea cycle, gluconeogenesis, 
TCA cycle etc. demonstrating 2 distinct molecular events occurring at the time of TCMR 
and PVAN (Figure 2).
RT-PCR validation of selected genes
In order to validate PVAN specific gene expression data, 4 genes (LTF, CFD, RPS15, and 
NOSIP) were selected for QPCR validation. As is illustrated in Figure 3, over-expression of 
all 4 genes in PVAN vs. STA and also in PVAN vs. TCMR was confirmed. In an 
independent set of PVAN (n=15), AR (n=18) and STA (n=18) fold increase in gene 
expression for; (i) lactotransferrin (LTF) in PVAN was significant when compared to AR 
(p=0.04) and STA (p=0.02), (ii) complement factor D (CFD) in PVAN was significant when 
compared to AR (p=0.05) and STA (p=0.05), (iii) 40 ribosomal protein S15 (RPS15) in 
PVAN was significant when compared to AR (p=0.002) and STA (p=0.02), (iv) nitric oxide 
synthase interacting protein (NOSIP) in PVAN was significant when compared to AR 
(p=0.004) and STA (p=0.007).
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Immunohistochemistry analysis of PVAN-associated gene products
Using immunohistochemistry (IHC) analysis, we assessed the expression of 2 gene 
transcripts (LTF and IFITM-1) at the protein level. These transcripts were highly 
upregulated in kidney biopsies with PVAN as compared to TCMR and STA and have been 
previously reported to have anti-viral properties, LTF (24,25) and IFITM1 (92,30) (Figure 
4a). As shown in Figure 4b, LTF and IFITM1 expression was significantly higher in both in 
tubulo-epithelial cells and within the mononuclear cellular infiltrates in PVAN patients as 
compared to STA and TCMR kidney transplant recipients.
Discussion
The advent of PVAN is still a major concern in kidney transplantation, as it accounts for the 
main cause of allograft loss. This is explained, in great part, to the rather poor understanding 
of the dominant mechanisms of the disease. While it is a widely accepted the fact that 
recognizing PVAN as early as possible is a key factor to increase the likelihood of success 5, 
it still remains unclear, which is the best treatment approach to follow. In this study, using 
high-throughput microarrays analysis we demonstrate that the inflammatory process 
occurring both in PVAN and TCMR, either due to a protective anti-viral or an allogeneic 
immune response, respectively, merges in a remarkably similar transcriptional gene pattern, 
essentially associated with effector immune pathways of both the adaptive and the innate 
immunity.
As reported earlier by other researchers 8,12, PVAN and TCMR share important similarities 
at the gene expression level, further helping to explain the difficulty of differentiating both 
types of diseases. In this regard, Mannon et al 8 evaluated target genes by qPCR in kidney 
allograft biopsies from recipients with PVAN, TCMR or patients with stable allograft 
function and showed that despite the significantly high resemblance of gene expression 
between PVAN and TCMR, transcription of certain molecules associated with graft fibrosis 
and markers of epithelial-mesenchymal transformation (EMT) were significantly higher in 
PVAN specimens, suggesting a higher profibrogenic transcriptional profile in PVAN than in 
TCMR patients. The higher tissue chronicity in the PVAN patient samples may also explain 
some of the observed differences between TCMR and PVAN relating to glucose and protein 
metabolism genes. Furthermore, in a recent study, Lubetzky and coworkers 12 evaluated 
gene expression in the whole blood as well as few kidney tissue allograft samples in PVAN 
and TCMR kidney transplant recipients. These studies have shown high levels of 
proinflammatory molecules in both settings, such as the interferon gamma-induced 
chemokines CXCL9 and CXCL10 11, as well as other Th-2-induced cytokines such as 
sIL-1RA, IL-3, IL-6, and sIL-6R, being particularly high in patients with high BK DNA 
replication 25.
Our study validated 4 PVAN-specific genes by qPCR and further confirmed using IHC. This 
illustrates the potential functional relevance of some of the particular transcripts uniquely 
expressed in PVAN biopsies as compared to rejecting patients. Firstly, Lactotransferrin 
(LTF), a member of the transferrin family found in mucous epithelial cells and secondary 
granules of polymorphonuclear neutrophils was highly differentially expressed among 
PVAN patients. Its expression in PVAN biopsies was significantly higher both within 
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cellular infiltrates and in tubulo-epithelial cells as compared to biopsies with TCMR and 
STA. in fact, LTF has been shown to play a key role in the defense against various 
pathogenic microorganisms, by inhibiting different enveloped 26,27 and naked 28,29 virus in 
different virus-cell systems. In addition, in experimental animal models it has been shown 
that oral administration of LTF or peptides thereof is effective in reducing bacterial 
infections and inflammation in the urinary tract, possibly through transfer of LTF or its 
peptides to the site of infection via renal secretion30. Of note, LTF treatment has been 
evaluated and shown to prevent early steps of BK virus infection in vitro, most likely 
through the interaction with BK viral capsidic structures 31. This finding is of relevance, 
since the high expression of LTF transcripts in kidney allografts infected by BK, might be 
the expression of a physiological protective response of the host against the virus in order to 
overcome the viral infection. Observation of increased expression of genes associated with 
TCA cycle, urea cycle, and gluconeogenesis is biologically plausible. Even though there is 
no report of increased metabolism in BKV infection, alteration of metabolism especially 
glucose metabolism and TCA cycle has been observed in case of cytomegalovirus 
infection32. It is intuitive to assume that successful replication of virus in the infected cells 
requires an environment that is suitable for increased supply of nutrient, energy, and 
macromolecular synthesis, which is reflected in the upregulated gene expression of genes 
related with metabolic pathways. Complment Factor D (CFD) was also upregulated in 
PVAN, which is a serine protease that cleaves C3b-bound factor B, resulting in the 
generation of Bb and formation of the alternative pathway C3 convertase (C3bBb) a key 
system for immune surveillance and homeostasis33. Increased expression of CFD and other 
complement genes shows activation of complement system at the time of viral infection. 
There is increased generation of nitric oxide (NO) due to viral infection, which is harmful34. 
NOSIP is 1 of the genes upregulated in PVAN, negatively regulates nitric oxide production 
by inducing translocation of NOS1 and NOS3 to actin cytoskeleton and inhibiting their 
enzymatic activities35. Furthermore, another highly up-regulated gene observed within 
PAVN patients as compared to TCMR and stable individuals was the IFN-inducible 
transmembrane 1 (IFITM-1) transcript. Interestingly, IFITM proteins are a family of 
ubiquitously expressed restriction factors that mediate potent IFN-induced antiviral activity 
by inhibiting viral entry, particularly the step of membrane fusion 36-38. Nevertheless, while 
IFITM-1 antiviral activity has been well characterized against RNA viruses 37,39,40, it has 
been shown to induce the opposite effect, that is to enhance infection of several DNA 
viruses. Indeed, it has been demonstrated that the antiviral activity of IFITM proteins is 
likely mediated by preventing endosome fusion and viral entry into the cytosol36-38, as well 
as inhibit viral entry by preventing escape from the endocytic pathway particularly among 
DNA virus41. Therefore, over-production of IFITM-1 molecules in PVAN patients could be 
hypothesized to represent a signal of persistent DNA replication, illustrating the aggressive 
nature of BKV infection in kidney transplantation. Indeed the co-localization of IFITM-1 in 
close proximity to LTF in tubular cells showing BK viral inclusions further corroborate these 
previously reported data (Figure 4).
In summary, even though PVAN and TCMR kidney allografts share great similarities on 
gene perturbation, particular PVAN-specific transcripts are differentially expressed, some of 
them encoding for molecules with well-known anti-viral properties. Further tracking such 
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effector molecules in the context of BK virus infection may lead to the discovery of novel 
potential therapeutic targets that may eventually overcome the development and persistence 
of BKV infection after kidney transplantation.
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Refer to Web version on PubMed Central for supplementary material.
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LTF Lactoferrin
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(A)- Global gene expression pattern of samples classified as PVAN were largely similar to 
TCMR samples when compared to normal kidney biopsies, BK viremia (BKVB), and 
IF/TA. (B)- Gene expression clustering demonstrates TCMR-specific gene signature. (C)- 
Gene expression clustering demonstrates PVAN-specific gene signature compared to normal 
(STA). A few genes (n=16) were also differentially expressed in the IF/TA patients 
compared to PVAN but this analysis is not as clean as many patients with PVAN also have 
associated IF/TA changes in the graft.
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A comprehensive pathway/gene-set analysis using the software GO-Elite was performed to 
identified molecular pathways enriched in PVAN compared to TCMR. This resulted in 
enrichment of 2 distinct set of pathways. Immune system related pathways such as 
complement cascade, TCR signaling, innate immune system, adaptive immune system were 
specific to TCMR whereas PVAN associated genes were enriched with DNA replication 
pathways such as mRNA processing, ribosomal scanning, viral mRNA translation etc. and 
metabolic pathways such as urea cycle, gluconeogenesis, TCA cycle etc. were specific to 
PVAN demonstrating 2 distinct molecular events occurring at the time of TCMR and PVAN.
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QPCR validations of PVAN specific genes. In order to validate PVAN specific gene 
expression data 4 genes (LTF, CFD, RPS15, and NOSIP) were selected for QPCR 
validation. Over-expression of all 4 genes in PVAN vs. STA and also in PVAN vs. TCMR 
was confirmed. Gene expression for; (A) lactotransferrin (LTF) in PVAN was significant 
when compared to AR (p=0.04) and STA (p=0.02), (B) complement factor D (CFD) in 
PVAN was significant when compared to AR (p=0.05) and STA (p=0.05), (C) 40 ribosomal 
protein S15 (RPS15) in PVAN was significant when compared to AR (p=0.002) and STA 
(p=0.02), (D) nitric oxide synthase interacting protein (NOSIP) in PVAN was significant 
when compared to AR (p=0.004) and STA (p=0.007). The first and third quartiles are at the 
ends of the box, the median is indicated with a horizontal line in the interior of the box, and 
the maximum and minimum are at the ends of the whiskers.
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Using immunohistochemistry (IHC) validation of PVAN specific expression of LTF and 
IFITM1 in kidney biopsies with PVAN. We assessed the expression of 2 gene transcripts 
(LTF and IFITM-1) at the protein level. These transcripts were highly upregulated in kidney 
biopsies with PVAN as compared to TCMR and STA. A) Three representatives phenotypes 
from 3 representative transplant patient biopsies evaluated for the different protein stains. 
TCMR and STA are shown at 10× and the PVAN samples are shown at 40× magnification. 
Co-localization of IFITM-1 with BK viral inclusions are marked with yellow arrows in the 
PVAN patient. LTF also localizes in proximity to the SV40 and IFITM-1 stains in the renal 
tubule. (B) Semi quantitative analysis of protein expression at tubulo-epithelial cells (TEC) 
and mononuclear cells of patients with PVAN, TCMR and STA.
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Table 1
Relevant Clinical Demographics.
Main clinical variables (n=168 patients and 
biopsies)
PVAN (n=10) TCMR (n=26) IFTA (n=59) STA
*
 (n=73) P value (>0.05=NS)
CNI-based (%) 100 100 100 100 NS
Mean donor age (yr±SD) 24±10 30±11 32±11 31±11 NS
Induction % IL2RmAb (induction useage is 
IL2RmAb or Thymoglobulin)
80 75 85 80 NS
%Steroid-free maintenance immunosuppression 60 58 65 70 NS
% prior history of acute rejection 15% 10% 8% 4% NS
Recipient gender (%F) 20 21 57 36 NS
Mean recipient age (yr±SD) 14±4 11±6 11±6 11±6 NS
Type of transplant (% living donor) 66 71 63 70 NS
Time post-transplant (mo±SD) 10±9 11±7 13±6 13±19 NS
Type of Biopsy (%Cause) 60 21 5 0 <0.0001
Serum creatinine at the timeof biopsy (mg/dL) 1.48±0.56 1.84±0.50 0.88±0.42 0.72±0.36 <0.0001
Kidney histology lesions (Banff score for each 
renal compartment;0-3) (mean±sd; range)
Acute Banff scores (range)
        Acute tubuli (t) 1.7±1 (1-3) 1.5±0.9 (1-3) 0.03±0.18(0-1) 0.03±0.18 (0-1) #
NS
        Acute Interstitium (i) 1.5±1.5 (1-2) 2.2±0.9 (1-3) 0.02±0.13(0-1) 0
        Acute glomeruli (ag) 0.1±0.3 (0-1) 0.2±0.3 (0-1) 0 0
        Acute vascular (av) 0 0 0 0
    Peritubular capilaritis (ptc) 0 0.3±0.5 (0-1) 0 0
        SV40 Positive Negative Negative Negative
    C4d 0 0 0 0
Chronic Banff scores (range) $
NS
    Chronic tubuli (ct) 1.3±0.9 (0-3) 0.7±0.5 (0-1) 1.3±1.1 (0-3) 0.32±0.54 (0-1) μ
p<0.0001
    Chronic interstitium (ci) 1.2±0.7 (0-2) 0.7±0.5 (0-1) 1.1±1.2 (0-2) 0
    Chronic vascular (cv) 0.3±0.5 (0-1) 0.2±0.4 (0-1) 0.5±0.8 0.28±0.46 (0-1)
    Chronic glomeruli (cg) 0.3±0.7 (0-2) 0 0.0±0.0 0
    BK viremia (copies/ml) (mean) 21262±38342 0 0 0
NS refers to a p>0.05
*
5 BKVB patients had stable graft function
#
PVAN and TCMR samples were not statistically significant regarding t and i scores (#NS).
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$
PVAN and IFTA samples were not statistically significant regarding the ct and ci scores ($NS)
μ
PVAN and IFTA were statistically different for ct and ci when compared to TCMR and STA (μp<0.0001) samples. All patients on steroid-free 
immunosuppression were not on steroids at the time of biopsy.
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